Drug intelligence / Profile preview

Feline UltraNasal

Development stage: Unknown
Lead developer: Elanco
Modality: Vaccines & Immunotherapeutics
Administration: Intranasal

Overview

Feline UltraNasal is a brand of veterinary intranasal vaccines for cats, originally developed by Heska Corporation and now part of Elanco's portfolio. These modified live virus vaccines are designed to provide rapid immunity against common feline diseases. Specific formulations, such as Feline UltraNasal FVRC and Feline UltraNasal FVRCP, protect against feline rhinotracheitis, calicivirus, and panleukopenia. The intranasal route of administration eliminates the risk of injection site sarcomas associated with injectable vaccines.

Brand names: Feline UltraNasal
Other names: Feline UltraNasal FVRCFeline UltraNasal FVRCP

Targets

FPV (Feline panleukopenia virus)

Beyond the preview

Go deeper on Feline UltraNasal.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Feline UltraNasal.

Explore the full profile